학술논문
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Document Type
Article
Author
Source
In European Journal of Cancer January 2017 70:146-155
Subject
Language
ISSN
0959-8049